CBLL vs KMTS
CBLL: Ceribell develops wearable EEG systems and AI-powered software for rapid, automated seizure detection and brain monitoring in acute care settings. KMTS: Kestra makes the ASSURE wearable cardioverter-defibrillator (WCD), a wireless cardiac monitoring and treatment device for patients at high risk of sudden cardiac death, as part of its Cardiac Recovery System platform.
Side-by-side fundamentals
| Metric | CBLL | KMTS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.82 | $20.89 | |
| Market cap as of 2026-07-23 | $638M | $1.3B | |
| Net margin as of 2026-07-23 | -63.5% | -173.0% | CBLL higher |
| Gross margin as of 2026-07-23 | +87.7% | +48.8% | CBLL higher |
| Operating margin as of 2026-07-23 | -68.3% | -171.5% | CBLL higher |
| ROE as of 2026-07-23 | -38.2% | -68.8% | CBLL higher |
| ROA as of 2026-07-23 | -30.9% | -48.8% | CBLL higher |
| Debt / equity as of 2026-07-23 | 0.14 | 0.15 | CBLL lower |
| Revenue growth (YoY) as of 2026-07-23 | +29.3% | +59.1% | KMTS higher |
| Revenue CAGR (3y) SEC XBRL | +40.3% | n/a | |
| Beta as of 2026-07-23 | 0.79 | 1.54 | |
| 1-year return as of 2026-07-22 close | +17.6% | +33.7% | KMTS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.